GRX-917 PIPELINE

The primary clinical development focus is getting GRX-917 approved in generalized anxiety disorder by 2030, since GAD is a derisked indication with large unmet medical need. Phase 3 registration trials in GAD are planned to commence in 2027.

NIH-ETSP recently demonstrated GRX-917 efficacy in three models of focal and generalizedepilepsy, which is predictive of human efficacy.

Additional large indications are supported by its mechanism of action and compelling preclinical efficacy data.